Teva Pharmaceutical Industries (TEVA) Competitors $16.43 -0.32 (-1.91%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TEVA vs. GSK, TAK, BNTX, BGNE, MRNA, VTRS, SMMT, GMAB, PCVX, and RDYShould you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include GSK (GSK), Takeda Pharmaceutical (TAK), BioNTech (BNTX), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Vaxcyte (PCVX), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Teva Pharmaceutical Industries vs. GSK Takeda Pharmaceutical BioNTech BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Vaxcyte Dr. Reddy's Laboratories Teva Pharmaceutical Industries (NYSE:TEVA) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends. Do analysts recommend TEVA or GSK? Teva Pharmaceutical Industries currently has a consensus target price of $19.67, suggesting a potential upside of 19.70%. GSK has a consensus target price of $43.25, suggesting a potential upside of 29.69%. Given GSK's higher possible upside, analysts plainly believe GSK is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78GSK 0 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 3 Strong Buy rating(s) 2.60 Which has higher earnings and valuation, TEVA or GSK? GSK has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$15.85B1.17-$559M-$0.85-19.33GSK$37.71B1.83$6.13B$1.5421.66 Is TEVA or GSK more profitable? GSK has a net margin of 7.97% compared to Teva Pharmaceutical Industries' net margin of -5.73%. GSK's return on equity of 50.62% beat Teva Pharmaceutical Industries' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-5.73% 42.92% 7.25% GSK 7.97%50.62%11.54% Which has more risk and volatility, TEVA or GSK? Teva Pharmaceutical Industries has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Does the MarketBeat Community believe in TEVA or GSK? Teva Pharmaceutical Industries received 511 more outperform votes than GSK when rated by MarketBeat users. Likewise, 67.77% of users gave Teva Pharmaceutical Industries an outperform vote while only 56.92% of users gave GSK an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes132567.77% Underperform Votes63032.23% GSKOutperform Votes81456.92% Underperform Votes61643.08% Do institutionals & insiders believe in TEVA or GSK? 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to TEVA or GSK? In the previous week, GSK had 10 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 19 mentions for GSK and 9 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.08 beat GSK's score of 0.12 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GSK 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryGSK beats Teva Pharmaceutical Industries on 12 of the 19 factors compared between the two stocks. Ad Investors AlleyStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!Click here to see this breakthrough before everyone else → Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TEVA vs. The Competition Export to ExcelMetricTeva Pharmaceutical IndustriesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$18.61B$6.39B$5.07B$19.81BDividend YieldN/A8.08%5.10%3.50%P/E Ratio-19.3310.92101.9242.29Price / Sales1.17245.131,196.9520.78Price / Cash4.8253.4941.0421.65Price / Book2.929.306.344.66Net Income-$559M$154.14M$119.64M$983.45M7 Day Performance-3.97%-9.47%-5.13%-2.12%1 Month Performance-8.52%-7.30%-2.72%-0.39%1 Year Performance81.35%28.21%31.10%23.34% Teva Pharmaceutical Industries Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TEVATeva Pharmaceutical Industries2.7777 of 5 stars$16.43-1.9%$19.67+19.7%+87.6%$18.61B$15.85B-19.3337,851Gap DownGSKGSK4.3173 of 5 stars$35.52-2.3%N/A-3.2%$73.62B$37.71B23.0770,200Analyst DowngradeGap DownTAKTakeda Pharmaceutical3.5607 of 5 stars$13.54-0.9%N/A-0.7%$43.07B$4.55T23.3449,281Short Interest ↓BNTXBioNTech3.4996 of 5 stars$106.32-2.2%N/A+0.0%$25.28B$4.13B-50.636,133Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownBGNEBeiGene3.0741 of 5 stars$193.64-5.6%N/A+0.0%$18.85B$2.46B-38.1210,600Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageMRNAModerna4.5626 of 5 stars$43.47+1.7%N/A-51.9%$16.71B$6.85B-7.475,600Analyst ForecastOptions VolumeGap DownHigh Trading VolumeVTRSViatris1.3727 of 5 stars$12.93-1.2%N/A+39.9%$15.43B$15.05B-17.4738,000Insider SellingSMMTSummit Therapeutics2.1933 of 5 stars$20.76-4.6%N/A+884.4%$15.31B$700,000.00-74.14105Gap UpGMABGenmab A/S4.4263 of 5 stars$22.47-3.1%N/A-35.6%$14.87B$19.84B21.822,204Short Interest ↑High Trading VolumePCVXVaxcyte3.3295 of 5 stars$99.38-4.1%N/A+73.3%$12.39BN/A-21.60160News CoverageRDYDr. Reddy's Laboratories1.3454 of 5 stars$14.76-1.6%N/A+6.7%$12.32B$299.87B23.5827,048Analyst DowngradeShort Interest ↑ Related Companies and Tools Related Companies GSK Alternatives TAK Alternatives BNTX Alternatives BGNE Alternatives MRNA Alternatives VTRS Alternatives SMMT Alternatives GMAB Alternatives PCVX Alternatives RDY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:TEVA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TEVA Stock Alerts